1. Home
  2. CTMX vs BKKT Comparison

CTMX vs BKKT Comparison

Compare CTMX & BKKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • BKKT
  • Stock Information
  • Founded
  • CTMX 2008
  • BKKT 2018
  • Country
  • CTMX United States
  • BKKT United States
  • Employees
  • CTMX N/A
  • BKKT N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • BKKT Computer Software: Prepackaged Software
  • Sector
  • CTMX Health Care
  • BKKT Technology
  • Exchange
  • CTMX Nasdaq
  • BKKT Nasdaq
  • Market Cap
  • CTMX 62.3M
  • BKKT 59.5M
  • IPO Year
  • CTMX 2015
  • BKKT N/A
  • Fundamental
  • Price
  • CTMX $0.58
  • BKKT $9.04
  • Analyst Decision
  • CTMX Buy
  • BKKT Hold
  • Analyst Count
  • CTMX 6
  • BKKT 2
  • Target Price
  • CTMX $5.77
  • BKKT $13.13
  • AVG Volume (30 Days)
  • CTMX 3.8M
  • BKKT 688.9K
  • Earning Date
  • CTMX 03-06-2025
  • BKKT 03-19-2025
  • Dividend Yield
  • CTMX N/A
  • BKKT N/A
  • EPS Growth
  • CTMX N/A
  • BKKT N/A
  • EPS
  • CTMX 0.38
  • BKKT N/A
  • Revenue
  • CTMX $138,103,000.00
  • BKKT $3,490,220,000.00
  • Revenue This Year
  • CTMX N/A
  • BKKT N/A
  • Revenue Next Year
  • CTMX N/A
  • BKKT N/A
  • P/E Ratio
  • CTMX $1.57
  • BKKT N/A
  • Revenue Growth
  • CTMX 36.45
  • BKKT 347.39
  • 52 Week Low
  • CTMX $0.56
  • BKKT $5.57
  • 52 Week High
  • CTMX $5.85
  • BKKT $37.21
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 37.64
  • BKKT 38.44
  • Support Level
  • CTMX $0.57
  • BKKT $8.51
  • Resistance Level
  • CTMX $0.65
  • BKKT $14.08
  • Average True Range (ATR)
  • CTMX 0.05
  • BKKT 1.42
  • MACD
  • CTMX 0.00
  • BKKT -0.03
  • Stochastic Oscillator
  • CTMX 15.04
  • BKKT 17.64

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About BKKT Bakkt Holdings Inc.

Bakkt Holdings Inc operates technology that connects the digital economy by offering a platform for crypto and redeeming loyalty points. Its institutional-grade technology platform provides a custody solution that caters to more experienced market participants to store crypto and provides consumers, businesses, and institutions with the ability to buy, sell, and store crypto in a simple, intuitive digital experience accessed via application programming interfaces (APIs) or embedded web experience and Loyalty offers a full spectrum of content that clients can make available to its customers when redeeming loyalty currencies. It generates revenue in the form of Subscription and service and Transaction revenue.

Share on Social Networks: